Cost-effectiveness Analysis of Four Kinds of Oral Hypoglycemic Drugs in Treating Diabetes
- VernacularTitle:4种口服降糖药治疗糖尿病的成本-效果分析
- Author:
Caijuan ZHU
;
Xia TAO
;
Yulin DENG
;
Li ZHANG
- Publication Type:Journal Article
- Keywords:
oral hypoglycemic drug;
pharmacoeconomics;
cost-effectiveness analysis
- From:
China Pharmacy
1991;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To select a best therapeutic scheme for diabetes among four kinds of oral hypoglycemic drugs:repaglinide(Novonorm),glibenclamide,gliclazide and glipizide.METHODS:According to the principle of pharmacoeconomics,using cost-effectiveness analysis(CEA),assessment and survey of the influencing factors(price,dosage)were carried out,at the same time,sensitive analysis was performed.RESULTS:The best therapeutic scheme was Novonorm and the rest were gliclazide,glipizide and glibenclamide in sequence.CONCLUSION:The result of sensitive analysis is in keeping with that of CEA,which indicates the credibility of CEA.
